Skip to content

Intuitive Surgical

NASDAQ: ISRG · USD

Intuitive Surgical (ISRG) Economic Moat Analysis50

Competitive advantages, dated evidence and erosion risks.

Narrow economic moat

Intuitive shows a narrow moat from installed-base and switching costs reinforced by multi‑year, non‑cancellable leases and recurring instruments/service revenue tied to procedure growth. Intangible assets (multi‑generation platforms, regulatory indications, and expanding reimbursement) support adoption. Pricing power is mixed: higher system ASPs contrast with mandated China instrument price cuts and purchaser consolidation. Competition and reimbursement pressure are key erosion risks.

Switching costs

Multi‑year, non‑cancellable operating leases and a growing installed base create contractual and operational frictions that support recurring monetization of instruments and services tied to procedure volume.

Durability
Scheduled non‑cancellable lease receipts extend through 2031 and instruments revenue growth tracks procedure growth, indicating persistence while leases run.
Competitors
Comparison not established
Erosion risks
Some customers use usage‑based models with contingent payments, reducing fixed commitments; China’s unified pricing cuts per‑procedure monetization; purchaser consolidation increases pricing pressure. No named competitor is specified in passages.
What would invalidate the thesis
Material customer lease terminations or a broad shift to cancellable per‑use models that shrink contracted lease backlogs, or sustained declines in instruments revenue per procedure in major markets.
Evidence (4) · Counterevidence (4)

Intangible assets

Differentiated, multi‑generation da Vinci platforms with proprietary technology, broad regulatory indications, and expanding reimbursement underpin provider adoption and program persistence.

Durability
Fifth‑generation features and ongoing additions to reimbursed procedures, including volume incentives in Japan, suggest continued clinical and economic validation.
Competitors
Comparison not established
Erosion risks
Competing surgical approaches and robotic systems and pricing/reimbursement pressures (e.g., China) can narrow differentiation and reduce economic returns.
What would invalidate the thesis
Loss of key regulatory indications, failure to secure reimbursement expansions, or rapid provider migration to rival platforms despite Intuitive’s updates.
Evidence (4) · Counterevidence (2)

Changes since the previous analysis

  • Verdict unchanged (narrow). This version adds explicit evidence of higher system ASPs and expected China instrument price reductions, and avoids unverified exit‑penalty claims; emphasis on non‑cancellable lease receipts and reimbursement expansions is retained.

Evidence limitations

  • Competitors are referenced generically in filings; no named competitor is provided for direct comparisons.
  • Recurring revenue share and retention metrics by cohort are not disclosed; installed‑base persistence is inferred from procedures and lease schedules.
  • Issuer disclosures dominate the dataset; independent third‑party clinical or market share data are absent.
  • Usage‑based lease cancellability is not explicitly stated; contingent nature limits inference of contractual lock‑in strength.

Financial indicators to test against the thesis

Calculated from annual filings. Missing data remains unavailable. Detailed financial charts remain in the other topics.

Financial indicators to test against the thesis
PeriodGross marginOperating marginROICFCF margin
202169.3%31.9%—30.4%
202267.4%25.3%—15.4%
202366.4%24.8%—10.5%
202467.5%28.1%—15.6%
202566.0%29.3%—24.7%

Pricing power50

  • Pricing outcomes

    Higher da Vinci system ASPs were realized, but mandatory China instrument price reductions and purchaser consolidation undermine broad pricing freedom.

  • Customer demand

    Procedure‑linked instruments demand and non‑cancellable lease receipts imply continued usage, though usage‑based leases’ contingent nature limits contractual stickiness and no renewal rates are provided.

  • Margin resilience

    Non‑GAAP gross margin outlook remains high despite tariff headwinds, indicating some resilience, but guidance embeds adverse tariff impact and does not isolate sustained pricing-driven margin defense.

  • Pricing freedom

    Contracts include per‑use fee structures and long‑dated operating leases, yet contingent usage‑based payments and government‑imposed price cuts (China) constrain unilateral pricing ability.

Management69

  • Capital discipline

    Robust operating cash flow and sizable but opportunistic buybacks and authorizations demonstrate active capital deployment; net cash declined with repurchases, and reinvestment returns are not quantified.

  • Incentive alignment

    PSUs vest on multi‑year procedure growth and relative operating margin, with recent vesting disclosed; ownership and clawback policies reinforce alignment.

  • Execution

    Strong revenue growth, rising placements, and lease installed base expansion indicate effective commercial execution across platforms in 2026.

  • Governance

    Independent board leadership, annual elections, enhanced clawback, and bylaw updates on shareholder nominations support sound governance practices.

Sources and methodology

Current publication · Updated 29/10/2026 · Version 11

AI interpretation based on checked source excerpts. Issuer assertions and evidence limitations remain explicit.

Policy quality-scores-3: six equally weighted categories. The overall score requires full coverage. Missing inputs are not zero. Qualitative grades are sourced interpretations, not probabilities. 4/6 · 29/10/2026

Moat50

Equal-weight average of four evidence-backed rubric grades (0–4), scaled to 100.

structural advantage · 2/4 · Non‑cancellable multi‑year lease receipts and growth in procedure‑linked instruments revenue indicate switching friction and embedded monetization, but usage‑based arrangements and purchaser consolidation temper breadth of protection.

durability · 2/4 · Lease cash flows extend across several years and reimbursement additions (e.g., Japan) support ongoing adoption; however, competitive and reimbursement pressures could erode advantages over time.

customer dependency · 2/4 · Instruments revenue scales with procedures, suggesting repeat demand from installed programs; explicit customer renewal or churn metrics are not disclosed.

erosion resilience · 2/4 · Revenue and instruments sales rose with procedures, and China limits were not yet material to the installed base, but mandated China price cuts and broader competitive pricing pressure are tangible threats.

Pricing power50

Equal-weight average of four evidence-backed rubric grades (0–4), scaled to 100.

realized pricing · 2/4 · Higher da Vinci system ASPs were realized, but mandatory China instrument price reductions and purchaser consolidation undermine broad pricing freedom.

retention · 2/4 · Procedure‑linked instruments demand and non‑cancellable lease receipts imply continued usage, though usage‑based leases’ contingent nature limits contractual stickiness and no renewal rates are provided.

margin resilience · 2/4 · Non‑GAAP gross margin outlook remains high despite tariff headwinds, indicating some resilience, but guidance embeds adverse tariff impact and does not isolate sustained pricing-driven margin defense.

contractual freedom · 2/4 · Contracts include per‑use fee structures and long‑dated operating leases, yet contingent usage‑based payments and government‑imposed price cuts (China) constrain unilateral pricing ability.

Predictability94

5 consecutive published annual periods. Equal weights: nondeclining revenue frequency; revenue-growth volatility (5–40pp); positive FCF frequency; FCF-margin volatility (3–20pp). Stability indicator, not a growth forecast.

Nondeclining revenue years (%)
100.00
Revenue growth volatility (pp)
4.23
Positive FCF years (%)
100.00
FCF margin volatility (pp)
7.19
observedAnnualPeriods
5.00

Financial strength—

Missing required inputs: debtFcfGrade, netDebtEbitGrade, interestCoverageGrade. Equal-weight grades: debt/FCF (1–8x), net debt/earnings before interest and tax (0–5x), interest service (1–12x), current ratio (0.75–2x). Earnings use reported operating income, an original issuer-reported unadjusted EBIT reconciled to net income, income tax and signed net interest, or reported pretax profit plus reported gross interest expense. Reported EBIT is distinct from GAAP operating income and gross interest. Interest service uses earnings/interest expense; if unavailable, it uses reported operating cash flow/cash interest paid, without relabeling cash paid as accrued expense. Nonpositive cash flow/earnings score 0 for their service component; reported zero interest with a positive numerator scores 100. Net cash scores 100 for net leverage. Missing disclosures remain unavailable. General nonfinancial-company rubric, not a credit rating; exceptional and nonoperating gains are not normalized out. IFRS finance-cost and cash-flow classifications retain their reported scope.

currentRatioGrade
100.00
Current ratio (x)
4.87

Capital allocation—

Missing required inputs: operatingReturn. Three-year equal-weight indicators: pretax return on average invested capital (0–25%; equity + debt − cash, each year and its prior year), share-count growth (0–5%, lower better), share-based cost/revenue (2–20%, lower better), consolidated FCF/net income (0–1x). Return uses reported operating income, an original issuer-reported unadjusted EBIT reconciled to net income, income tax and signed net interest, or EBIT calculated from reported pretax profit plus reported gross interest expense; the issuer-reported EBIT is distinct from GAAP operating income and gross interest; exceptional/nonoperating gains are not normalized out. Share-based cost uses the reported cash-flow add-back or, if absent, separately reported recognized compensation expense; the latter never becomes an FCF adjustment. Nonpositive net income scores 0 for cash conversion; absent income/FCF stays unavailable. ROIC remains undefined for nonpositive invested capital; the explicit asset-return alternative does not change the ROIC chart. Missing financial inputs alone never trigger an alternative. Does not establish acquisition quality or buyback timing.

3-year average dilution (%)
0.12
3-year average SBC / revenue (%)
8.09
cashConversionGrade
65.13

Management69

Equal-weight average of four evidence-backed rubric grades (0–4), scaled to 100.

capital discipline · 2/4 · Robust operating cash flow and sizable but opportunistic buybacks and authorizations demonstrate active capital deployment; net cash declined with repurchases, and reinvestment returns are not quantified.

incentive alignment · 3/4 · PSUs vest on multi‑year procedure growth and relative operating margin, with recent vesting disclosed; ownership and clawback policies reinforce alignment.

execution · 3/4 · Strong revenue growth, rising placements, and lease installed base expansion indicate effective commercial execution across platforms in 2026.

governance · 3/4 · Independent board leadership, annual elections, enhanced clawback, and bylaw updates on shareholder nominations support sound governance practices.

Evidence

Future lease payments (excluding non-lease elements and contingent payments related to usage-based arrangements) related to the non-cancellable portion of operating leases as of December 31, 2025, are as follows (in millions): Fiscal Year Amount 2026 $ 326.1 2027 269.7 2028 208.6 2029 151.1 2030 83.5 2031 and thereafter 61.9 Total $ 1,100.9 Lessee Information The Company enters into operating leases primarily for real estate, automobiles, and certain equipment.

Intuitive System Leasing; future non‑cancellable operating lease receipts · Filed 03/02/2026

393.4 Operating Leases. The Company’s fixed-payment or usage-based operating lease terms are generally less than seven years.

Intuitive System Leasing; excludes contingent usage‑based payments from non‑cancellable lease schedule · Filed 31/01/2025

The Company also leases systems to certain qualified customers under usage-based arrangements that have terms of up to 84 months.

Intuitive System Leasing; usage‑based leases billed per‑use monthly · Filed 31/01/2024

Second quarter 2026 instruments and accessories revenue increased by 18% to $1.73 billion, compared with $1.47 billion in the second quarter of 2025.

Earnings release; instruments revenue driven by procedure growth · Filed 16/07/2026

Third quarter 2026 instruments and accessories revenue increased by 18% to $1.80 billion, compared with $1.52 billion in the third quarter of 2025.

Earnings release; instruments revenue increase tied to da Vinci and Ion procedures · Filed 20/10/2026

The higher third quarter revenue was driven by growth in procedure volume, higher operating lease revenue, and an increase in the installed base of systems.

Earnings release; revenue driven by procedure volume, higher lease revenue, and installed base · Filed 20/10/2026

The higher systems revenue reflected a higher lease installed base, higher da Vinci system average selling prices, and increased da Vinci system placements compared with the second quarter of 2025.

Earnings release; higher da Vinci system average selling prices · Filed 16/07/2026

Beginning in the fourth quarter of 2026, we expect to implement price reductions on instruments sold in China in response to the continued rollout of the NHSA unified national pricing framework.

10‑Q; China NHSA unified pricing leads to instrument price reductions and lower revenue per procedure · Filed 21/10/2026

Numerous initiatives and reforms by legislators, regulators, and third-party payers to curb the rising cost of healthcare have catalyzed a consolidation of aggregate purchasing power within the markets in which we sell our products.

10‑K risk factors; purchaser consolidation intensifies competition and pricing pressures · Filed 31/01/2025

approvals, clearances, certifications, and restrictions or any dispute that may occur with any regulatory body; healthcare reform legislation in the U.S.

Earnings release forward‑looking statements; competition from alternative approaches and robotic systems, including domestic competitors in China · Filed 20/10/2026

There are several models of the da Vinci surgical system currently used by our customers: our recently released fifth-generation da Vinci 5 surgical system, our fourth-generation da Vinci X, da Vinci Xi, and da Vinci SP surgical systems, our third-generation da Vinci Si surgical system, and our second-generation da Vinci S surgical system.

10‑K; multiple da Vinci models including fifth‑generation da Vinci 5 · Filed 31/01/2025

Our recently released da Vinci 5 surgical system builds on da Vinci Xi’s highly functional design, featuring force feedback technology and instruments that enable surgeons to sense and measure the force exerted on tissue during surgery.

10‑K; da Vinci 5 features such as force feedback and next‑gen imaging · Filed 03/02/2026

In April 2026, an additional seven da Vinci procedures were granted reimbursement, including inguinal hernia repair, effective in June 2026.

10‑Q; Japan adds reimbursed da Vinci procedures and volume‑based incentives · Filed 21/10/2026

Intuitive®, Intuitive Surgical®, da Vinci®, da Vinci S®, da Vinci Si®, da Vinci X®, da Vinci Xi®, da Vinci 5™, da Vinci SP®, EndoWrist®, Firefly®, Flexision®, Intuitive 3D Models™, Intuitive Hub™, Ion®, My Intuitive™, OnSite®, SimNow®, SureForm®, and SynchroSeal® are trademarks or registered trademarks of the Company.

10‑K; trademarks and brand assets · Filed 31/01/2025

The following table summarizes our cash flows for the periods presented (in millions): Six Months Ended June 30, 2026 2025 Net cash provided by (used in): Operating activities $ 1,972.9 $ 1,297.0 Investing activities (941.1) 474.2 Financing activities (1,641.6) (383.6) Effect of exchange rates on cash, cash equivalents, and restricted cash 8.1 (3.5) Net increase (decrease) in cash, cash equivalents, and restricted cash $ (601.7) $ 1,384.1

10‑Q; strong operating cash flow · Filed 21/07/2026

•The Company repurchased 7.8 million shares of its common stock for $2.94 billion in the third quarter of 2026.

Earnings release; significant share repurchases · Filed 20/10/2026

The most recent authorization occurred in April 2026, when the Board increased the authorized amount available under the Repurchase Program to $5.0 billion, including amounts remaining under previous authorizations.

10‑Q; repurchase authorization increased to $5.0 billion · Filed 21/10/2026

The 2023 PSU awards vested in the first quarter of 2026.

10‑Q; PSU metrics and vesting tied to procedure growth and relative margins · Filed 21/10/2026

Our key corporate governance practices are summarized below.

Proxy; independent board, separate Chair/CEO, annual elections · Filed 13/03/2026

Clawback Policy Our Clawback Policy (the “Policy”) is intended to comply with SEC and Nasdaq listing standards and maintain a culture of focused, diligent, and responsible management that discourages conduct detrimental to the growth of the Company.

Proxy; clawback policy and 2026 enhancement · Filed 13/03/2026

In addition, as overall competition for medical technologies, including robotic-assisted devices and other treatment options, progresses in various markets, longer selling cycles and pricing pressures are likely to result.

10‑K risk factors; competition likely to extend selling cycles and pressure pricing · Filed 31/01/2024

•Non-GAAP* gross profit margin to be within a range of 68.7% to 69.3% of revenue in 2026.

Earnings release; non‑GAAP gross margin outlook including tariff impact · Filed 20/10/2026

As of the date of this report, the limits that have been implemented have not had a material impact on our business, financial condition, or results of operations, as only a small portion of our installed base in China is currently located in impacted provinces.

10‑Q; China provincial limits not yet material given small installed base in impacted areas · Filed 21/10/2026

The second quarter 2026 da Vinci surgical system placements included 254 systems placed under operating lease arrangements, of which 131 systems were placed under usage-based operating lease arrangements, compared with 193 systems placed under operating lease arrangements, of which 124 systems were placed under usage-based operating lease arrangements in the second quarter of 2025.

Earnings release; higher lease installed base and usage‑based placements · Filed 16/07/2026

(the “Company”) amended and restated the Company’s Amended and Restated Bylaws (as so amended and restated, the “Amended Bylaws”) to, among other things:

8‑K; amended bylaws clarifying shareholder nomination procedures · Filed 27/07/2026

Publication history

Publication history
VersionUpdatedCompetitive advantage
1129/10/2026narrow
1029/10/2026narrow
928/10/2026narrow
824/10/2026narrow
723/10/2026narrow
622/10/2026narrow
519/10/2026narrow
418/10/2026narrow
318/10/2026narrow
218/10/2026narrow

Sources

Research methodology and limitations · What is an economic moat?